全球糖尿病前期市场规模、份额、趋势和成长分析报告（2026-2034年）

预计糖尿病前期市场将从 2025 年的 2.5937 亿美元成长到 2034 年的 5.0693 亿美元，2026 年至 2034 年的复合年增长率为 7.73%。

全球糖尿病前期市场预计将迎来显着成长，这主要得益于糖尿病前期盛行率的不断上升以及人们对糖尿病前期健康影响的认识不断提高。糖尿病前期是一种血糖值升高但尚未达到糖尿病诊断标准的疾病，影响着全球数百万人口。随着医疗服务提供者和患者逐渐认识到早期疗育对于预防第2型糖尿病发展的重要性，对糖尿病前期筛检、诊断工具和管理解决方案的需求预计将大幅增长，从而推动这一关键市场的创新和投资。

此外，数位健康技术和个人化医疗的进步预计将进​​一步推动糖尿病前期市场的发展。行动医疗应用、穿戴式装置和远距医疗平台的开发将使人们能够监测血糖值、追踪生活方式的改变，并获得医疗专业人员的个人化指导。此外，随着人们越来越重视包括饮食改善和体能活动在内的生活方式改善计划，对能够帮助个人主导自身健康的综合管理解决方案的需求也日益增长。随着医疗保健格局的不断演变，预计糖尿病前期解决方案市场将迎来对满足多样化患者需求的创新产品和服务的激增。

此外，对监管合规和公共卫生倡议日益重视预计将塑造糖尿病前期市场的未来。随着各国政府和医疗机构实施旨在提高公众意识和推广预防措施的项目，对糖尿病前期筛检和管理解决方案的需求将持续增长。医疗服务提供者、技术开发商和监管机构之间的合作对于推动这些发展并确保糖尿病前期市场能够持续满足患者和医疗系统不断变化的需求至关重要。

目录

第一章 引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场问题
• 波特五力分析
• PESTLE分析

第四章：全球糖尿病前期市场：依药物类别划分

• 市场分析、洞察与预测
• 甲胍
• 胰岛素增敏剂
• Glucagon-Like Peptide-1促效剂（GLP-1）
• SGLT2抑制剂
• DPP-4抑制剂
• 其他的

第五章：全球糖尿病前期市场：依年龄组别划分

• 市场分析、洞察与预测
• 儿童（12-18岁）
• 成年人（18-49岁）
• 老年人（50岁以上）

第六章 全球糖尿病前期市场：依地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第七章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第八章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Novo Nordisk
  • Valbiotis
  • Resverlogix
  • Caelus Health
  • SciMar
  • Boston Therapeutics
  • Aphaia Pharma
  • AstraZeneca
  • Bristol-Myers Squibb

The Prediabetes Market size is expected to reach USD 506.93 Million in 2034 from USD 259.37 Million (2025) growing at a CAGR of 7.73% during 2026-2034.

The global prediabetes market is poised for significant growth, driven by the increasing prevalence of prediabetes and the rising awareness of its health implications. Prediabetes, characterized by elevated blood sugar levels that are not yet high enough to be classified as diabetes, affects millions of individuals worldwide. As healthcare providers and patients recognize the importance of early intervention to prevent the progression to type 2 diabetes, the demand for screening, diagnostic tools, and management solutions for prediabetes is expected to rise substantially, fostering innovation and investment in this critical market.

Moreover, advancements in digital health technologies and personalized medicine are anticipated to further boost the prediabetes market. The development of mobile health applications, wearable devices, and telehealth platforms enables individuals to monitor their blood sugar levels, track lifestyle changes, and receive personalized guidance from healthcare professionals. Additionally, the growing emphasis on lifestyle modification programs, including dietary changes and physical activity, is driving the demand for comprehensive management solutions that empower individuals to take control of their health. As the healthcare landscape continues to evolve, the market for prediabetes solutions is likely to witness a surge in demand for innovative products and services that cater to diverse patient needs.

In addition, the increasing focus on regulatory compliance and public health initiatives is expected to shape the future of the prediabetes market. As governments and health organizations implement programs aimed at raising awareness and promoting preventive measures, the demand for prediabetes screening and management solutions will continue to rise. Collaborative efforts between healthcare providers, technology developers, and regulatory bodies will be essential in driving these advancements, ensuring that the prediabetes market remains responsive to the evolving needs of patients and healthcare systems.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drug Class

• Biguanide
• Thiazolidinediones
• Glucagon-Like Peptide-1 Agonists (GLP-1)
• SGLT2 Inhibitors
• DPP-4 Inhibitors
• Others

By Age Group

• Children (12-18 Years)
• Adults (18-49)
• Elderly (50+)

COMPANIES PROFILED

• Novo Nordisk, Valbiotis, Resverlogix, Caelus Health, SciMar, Boston Therapeutics, Aphaia Pharma, AstraZeneca, BristolMyers Squibb

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL PREDIABETES MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug Class
• 4.2. Biguanide Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Thiazolidinediones Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Glucagon-Like Peptide-1 Agonists (GLP-1) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. SGLT2 Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. DPP-4 Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL PREDIABETES MARKET: BY AGE GROUP 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Age Group
• 5.2. Children (12-18 Years) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Adults (18-49) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Elderly (50+) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL PREDIABETES MARKET: BY REGION 2022-2034(USD MN)

• 6.1. Regional Outlook
• 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.2.1 By Drug Class
  • 6.2.2 By Age Group
  • 6.2.3 United States
  • 6.2.4 Canada
  • 6.2.5 Mexico
• 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.3.1 By Drug Class
  • 6.3.2 By Age Group
  • 6.3.3 United Kingdom
  • 6.3.4 France
  • 6.3.5 Germany
  • 6.3.6 Italy
  • 6.3.7 Russia
  • 6.3.8 Rest Of Europe
• 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.4.1 By Drug Class
  • 6.4.2 By Age Group
  • 6.4.3 India
  • 6.4.4 Japan
  • 6.4.5 South Korea
  • 6.4.6 Australia
  • 6.4.7 South East Asia
  • 6.4.8 Rest Of Asia Pacific
• 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.5.1 By Drug Class
  • 6.5.2 By Age Group
  • 6.5.3 Brazil
  • 6.5.4 Argentina
  • 6.5.5 Peru
  • 6.5.6 Chile
  • 6.5.7 South East Asia
  • 6.5.8 Rest of Latin America
• 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.6.1 By Drug Class
  • 6.6.2 By Age Group
  • 6.6.3 Saudi Arabia
  • 6.6.4 UAE
  • 6.6.5 Israel
  • 6.6.6 South Africa
  • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

• 7.1. Recent Developments
• 7.2. Company Categorization
• 7.3. Supply Chain & Channel Partners (based on availability)
• 7.4. Market Share & Positioning Analysis (based on availability)
• 7.5. Vendor Landscape (based on availability)
• 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL PREDIABETES INDUSTRY

• 8.1. Top Companies Market Share Analysis
• 8.2. Company Profiles
  • 8.2.1 Novo Nordisk
  • 8.2.2 Valbiotis
  • 8.2.3 Resverlogix
  • 8.2.4 Caelus Health
  • 8.2.5 SciMar
  • 8.2.6 Boston Therapeutics
  • 8.2.7 Aphaia Pharma
  • 8.2.8 AstraZeneca
  • 8.2.9 Bristol-Myers Squibb